Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albrecht Stoehr

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Journal of Hepatology|February 27, 2013
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatmentEric Lawitz, Maribel Rodriguez-Torres, Albrecht Stoehr, et al.
AIDS (London, England)|February 16, 2007
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1Christine Katlama, Roberto Esposito, Jose M Gatell, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|February 17, 2022
[HIV First Diagnoses in Germany in 2014 - A Regional Analysis]Benjamin Thomas Schleenvoigt, Juliane Ankert, Hartmut Stocker, et al.
Blood|May 21, 2005
AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotypingChristian Hoffmann, Markus Tiemann, Carsten Schrader, et al.
Infection|May 13, 2020
High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort studyMarkus Bickel, Christian Hoffmann, Eva Wolf, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjectsGraeme Moyle, Marta Boffito, Albrecht Stoehr, et al.
Hepatology (Baltimore, Md.)|April 5, 2012
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II studyMichael P Manns, Edward Gane, Maribel Rodriguez-Torres, et al.
Plos One|September 20, 2014
Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3Claus Niederau, Stefan Mauss, Andreas Schober, et al.
Leukemia & Lymphoma|October 27, 2006
AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effectiveChristian Hoffmann, Eva Wolf, Christoph Wyen, et al.
Journal of Hepatology|March 13, 2019
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infectionDavid Wyles, Ola Weiland, Betty Yao, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Journal of Hepatology|February 27, 2013
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatmentEric Lawitz, Maribel Rodriguez-Torres, Albrecht Stoehr, et al.
AIDS (London, England)|February 16, 2007
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1Christine Katlama, Roberto Esposito, Jose M Gatell, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|February 17, 2022
[HIV First Diagnoses in Germany in 2014 - A Regional Analysis]Benjamin Thomas Schleenvoigt, Juliane Ankert, Hartmut Stocker, et al.
Blood|May 21, 2005
AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotypingChristian Hoffmann, Markus Tiemann, Carsten Schrader, et al.
Infection|May 13, 2020
High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort studyMarkus Bickel, Christian Hoffmann, Eva Wolf, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjectsGraeme Moyle, Marta Boffito, Albrecht Stoehr, et al.
Hepatology (Baltimore, Md.)|April 5, 2012
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II studyMichael P Manns, Edward Gane, Maribel Rodriguez-Torres, et al.
Plos One|September 20, 2014
Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3Claus Niederau, Stefan Mauss, Andreas Schober, et al.
Leukemia & Lymphoma|October 27, 2006
AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effectiveChristian Hoffmann, Eva Wolf, Christoph Wyen, et al.
Journal of Hepatology|March 13, 2019
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infectionDavid Wyles, Ola Weiland, Betty Yao, et al.
Pageof 6